{"title":"倡导者敦促 FDA 终止氯氮平的 REMS 要求","authors":"Valerie A. Canady","doi":"10.1002/mhw.34216","DOIUrl":null,"url":null,"abstract":"<p>The Treatment Advocacy Center (TAC) and other advocates are trying to convince the Food and Drug Administration (FDA) to end the Risk Evaluation and Mitigation Strategy (REMS) requirements for clozapine. The requirements, they said, reduce the number of providers who will prescribe this “gold standard medication” that works for many people with serious mental illness.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advocates urge FDA to end REMS requirements for clozapine\",\"authors\":\"Valerie A. Canady\",\"doi\":\"10.1002/mhw.34216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The Treatment Advocacy Center (TAC) and other advocates are trying to convince the Food and Drug Administration (FDA) to end the Risk Evaluation and Mitigation Strategy (REMS) requirements for clozapine. The requirements, they said, reduce the number of providers who will prescribe this “gold standard medication” that works for many people with serious mental illness.</p>\",\"PeriodicalId\":100916,\"journal\":{\"name\":\"Mental Health Weekly\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34216\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Advocates urge FDA to end REMS requirements for clozapine
The Treatment Advocacy Center (TAC) and other advocates are trying to convince the Food and Drug Administration (FDA) to end the Risk Evaluation and Mitigation Strategy (REMS) requirements for clozapine. The requirements, they said, reduce the number of providers who will prescribe this “gold standard medication” that works for many people with serious mental illness.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
